Nurix therapeutics announces clearance of investigational new drug application for nx-1607 supporting plans to expand enrollment to u.s. clinical sites

Nx-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types
NRIX Ratings Summary
NRIX Quant Ranking